{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:58Z","timestamp":1787999878864,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPC KAKENHI","award":["JP20H03592"],"award-info":[{"award-number":["JP20H03592"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00415-020-10213-x","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T14:02:07Z","timestamp":1599746527000},"page":"680-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature"],"prefix":"10.1007","volume":"268","author":[{"given":"Kensuke","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-4574","authenticated-orcid":false,"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"10213_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","volume":"13","author":"I Bot","year":"2013","unstructured":"Bot I, Blank CU, Boogerd W, Brandsma D (2013) Neurological immune-related adverse events of ipilimumab. Pract Neurol 13:278\u2013280","journal-title":"Pract Neurol"},{"key":"10213_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-018-0318-x","volume":"6","author":"L Cafuir","year":"2018","unstructured":"Cafuir L, Lawson D, Desai N, Kesner V, Voloschin A (2018) Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. J Immunother Cancer 6:11","journal-title":"J Immunother Cancer"},{"key":"10213_CR3","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","volume":"130","author":"X Chen","year":"2019","unstructured":"Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B (2019) Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 130:1440\u20131445","journal-title":"Clin Neurophysiol"},{"key":"10213_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138","journal-title":"Eur J Cancer"},{"key":"10213_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1515584","volume":"375","author":"MF de Maleissye","year":"2016","unstructured":"de Maleissye MF, Nicolas G, Saiag P (2016) Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375:296\u2013297","journal-title":"N Engl J Med"},{"key":"10213_CR6","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93:e1093\u2013e1103","journal-title":"Neurology"},{"key":"10213_CR7","first-page":"534","volume":"381","author":"Y Fukumoto","year":"2017","unstructured":"Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S (2017) Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry 381:534","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10213_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6:83","journal-title":"J Immunother Cancer"},{"key":"10213_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard MA, Grob JJ (2013) A severe case of ipilimumab-induced Guillain\u2013Barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36:77\u201378","journal-title":"J Immunother"},{"key":"10213_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","volume":"45","author":"Y Gu","year":"2017","unstructured":"Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G (2017) Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 45:14\u201317","journal-title":"J Clin Neurosci"},{"key":"10213_CR11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","volume":"142","author":"A Jacob","year":"2016","unstructured":"Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S (2016) A case of fatal Guillain\u2013Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol 142:1869\u20131870","journal-title":"J Cancer Res Clin Oncol"},{"key":"10213_CR12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74:1216\u20131222","journal-title":"JAMA Neurol"},{"key":"10213_CR13","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/j.clgc.2018.11.022","volume":"17","author":"A Kyriazoglou","year":"2019","unstructured":"Kyriazoglou A, Liontos M, Papadopoulos C, Bilali A, Kostouros E, Pagoni S, Doumas K, Dimopoulos MA, Bamias A (2019) Guillain\u2013Barre syndrome related to Nivolumab: case report of a patient with urothelial cancer and review of the literature. Clin Genitourin Cancer 17:e360\u2013e364","journal-title":"Clin Genitourin Cancer"},{"key":"10213_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16:589\u2013593","journal-title":"Neuro Oncol"},{"key":"10213_CR15","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","volume":"265","author":"S Mancone","year":"2018","unstructured":"Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ, Strowd RE (2018) Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol 265:1636\u20131642","journal-title":"J Neurol"},{"key":"10213_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jns.2018.04.028","volume":"390","author":"T Nukui","year":"2018","unstructured":"Nukui T, Nakayama Y, Yamamoto M, Taguchi Y, Dougu N, Konishi H, Hayashi T, Nakatsuji Y (2018) Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain\u2013Barre syndrome. J Neurol Sci 390:115\u2013116","journal-title":"J Neurol Sci"},{"key":"10213_CR17","first-page":"107","volume":"28","author":"AS Patel","year":"2019","unstructured":"Patel AS, Snook RJ, Sehdev A (2019) Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discov Med 28:107\u2013111","journal-title":"Discov Med"},{"key":"10213_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma Ex change\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group","year":"1997","unstructured":"Plasma Ex change\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barre syndrome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barre Syndrome Trial Group. Lancet 349:225\u2013230","journal-title":"Lancet"},{"key":"10213_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2340\/00015555-2548","volume":"97","author":"R Schneiderbauer","year":"2017","unstructured":"Schneiderbauer R, Schneiderbauer M, Wick W, Enk AH, Haenssle HA, Hassel JC (2017) PD-1 antibody-induced Guillain\u2013Barre syndrome in a patient with metastatic melanoma. Acta Derm Venereol 97:395\u2013396","journal-title":"Acta Derm Venereol"},{"key":"10213_CR20","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1002\/mus.25672","volume":"56","author":"M Sepulveda","year":"2017","unstructured":"Sepulveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgas N, Casanova-Molla J, Graus F (2017) Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve 56:E162\u2013E167","journal-title":"Muscle Nerve"},{"key":"10213_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CND.0000000000000193","volume":"19","author":"S Supakornnumporn","year":"2017","unstructured":"Supakornnumporn S, Katirji B (2017) Guillain\u2013Barre syndrome triggered by immune checkpoint inhibitors: a case report and literature review. J Clin Neuromuscul Dis 19:80\u201383","journal-title":"J Clin Neuromuscul Dis"},{"key":"10213_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134","journal-title":"Neurology"},{"key":"10213_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jjco\/hyw090","volume":"46","author":"R Tanaka","year":"2016","unstructured":"Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, Okune M, Inoue S, Sekine I, Tamaoka A, Fujimoto M (2016) Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain\u2013Barre syndrome: a case report. Jpn J Clin Oncol 46:875\u2013878","journal-title":"Jpn J Clin Oncol"},{"key":"10213_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000070","volume":"38","author":"I Thaipisuttikul","year":"2015","unstructured":"Thaipisuttikul I, Chapman P, Avila EK (2015) Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 38:77\u201379","journal-title":"J Immunother"},{"key":"10213_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/annonc\/mdr028","volume":"22","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof S, Neyns B (2011) Anti-CTLA-4 antibody-induced Guillain\u2013Barre syndrome in a melanoma patient. Ann Oncol 22:991\u2013993","journal-title":"Ann Oncol"},{"key":"10213_CR26","doi-asserted-by":"publisher","first-page":"e1104","DOI":"10.1016\/j.clgc.2019.07.020","volume":"17","author":"N Yildirim","year":"2019","unstructured":"Yildirim N, Gonen M, Balgetir F, Er MB (2019) Fatal acute motor axonal neuropathy induced by Nivolumab: a case report and literature review. Clin Genitourin Cancer 17:e1104\u2013e1107","journal-title":"Clin Genitourin Cancer"},{"key":"10213_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/CND.0000000000000230","volume":"20","author":"C Yuen","year":"2019","unstructured":"Yuen C, Kamson D, Soliven B, Kramer C, Goldenberg F, Rezania K (2019) Severe relapse of vaccine-induced Guillain\u2013Barre syndrome after treatment with Nivolumab. J Clin Neuromuscul Dis 20:194\u2013199","journal-title":"J Clin Neuromuscul Dis"},{"key":"10213_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225","journal-title":"Eur J Cancer"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10213-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10213-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T23:42:03Z","timestamp":1631144523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10213-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10213"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10213-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"19 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KeO, MS, HY, KS, TM, SY, KoO, and JN declare no competing interests. SS is a consultant\/advisory board member on neurologic side effects for Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Chugai, and Astra Zeneca. Outside of the submitted work, SS reports personal fees from Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Chugai, and Astra Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Institutional Review Boards of the Keio University (No. 20090278).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Approved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Approved.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}